Zepbound Dry Mouth: Is It a Listed Side Effect?
Zepbound dry mouth is a listed side effect, reported at a low rate. The Zepbound label says dry mouth or dry throat was reported by 1% of people on Zepbound and 0.1% on placebo, in its two main weight-loss trials pooled.
That rate is under the 2% cut-off for the label's main side effect table, so it sits in a short paragraph of its own. The Mounjaro label, for the same drug, has no dry mouth entry at all.
Short answer
- Is dry mouth on the Zepbound label?
- Yes. Dry mouth or dry throat: 1% on Zepbound against 0.1% on placebo.
- Is it on the Mounjaro label?
- No. A full-text search of the US Mounjaro label found no dry mouth, dry throat or xerostomia entry.
- Is thirst listed?
- No. The Zepbound label has no thirst entry. It does warn that diarrhea, nausea and vomiting may cause fluid loss.
Sources: Zepbound FDA label; Mounjaro FDA label
Dry mouth on the Zepbound label
The label has a short entry headed Dry Mouth. It reads that in a pool of Study 1 and 2, dry mouth or dry throat was reported by 1% of Zepbound-treated patients and 0.1% of placebo-treated patients.
Why is it not in the big table? Table 1 of the label only covers adverse reactions seen in 2% or more of Zepbound users and more often than on placebo. At 1%, dry mouth falls below that line, so the label reports it in the text under the table.
The label gives one figure, not one per dose, and no figure for how long dry mouth lasted. It also does not say what caused it.
Sources: Zepbound FDA label
Mouth and fluid entries across the two tirzepatide labels
Zepbound and Mounjaro both contain tirzepatide, but only Zepbound lists dry mouth. This table puts the mouth and fluid entries from both US labels side by side.
| Entry | Zepbound label | Mounjaro label |
|---|---|---|
| Dry mouth or dry throat | 1% on Zepbound vs 0.1% on placebo (Studies 1 and 2 pooled) | No entry found |
| Taste change (dysgeusia) | 0.4% on Zepbound vs no one on placebo | Not part of this check |
| Thirst | No entry found | Not part of this check |
| Saliva or xerostomia | No entry found | No xerostomia entry found |
| Stomach side effects (any) | 56% on each dose vs 30% on placebo | Not part of this check |
| Fluid loss warning | Drink fluids to help reduce the chance of dehydration | Advise precautions to avoid fluid depletion |
Neither label explains why one lists dry mouth and the other does not. For the wider story of the two brands, see is Zepbound the same as Mounjaro.
Sources: Zepbound FDA label; Mounjaro FDA label
Can Zepbound dehydrate you?
The label says its stomach side effects can. The patient information says diarrhea, nausea and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems, and that it is important to drink fluids to help reduce the chance of dehydration.
Stomach side effects are common on Zepbound. The label reports them in 56% of people on each Zepbound dose, against 30% on placebo.
The prescribing information links fluid loss to kidney harm. It says most reported kidney injury cases occurred in people whose stomach side effects, such as nausea, vomiting or diarrhea, led to dehydration. The Mounjaro label tells prescribers to inform patients of this risk and to advise precautions to avoid fluid depletion.
For the most common cause of that fluid loss, see tirzepatide diarrhea.
Sources: Zepbound FDA label; Mounjaro FDA label
Why does Zepbound make me so thirsty?
No official source says it does. A full-text search of the Zepbound label found no entry for thirst, and a PubMed search for tirzepatide and thirst found no study.
What the label does report sits close by: dry mouth or dry throat at 1%, and fluid loss from diarrhea, nausea and vomiting. Strong or new thirst can have other causes, so it is something to raise with a clinician rather than put down to the drug.
Sources: Zepbound FDA label
Why a GLP-1 drug might cause dry mouth: proposed causes
Researchers have proposed causes, but none is proven. A 2026 review of GLP-1 drugs and the mouth names three:
- Changes in signaling (cyclic AMP) inside the saliva-making cells.
- Changes in the nerve control of saliva flow.
- Dehydration from stomach and bowel side effects.
A review of semaglutide adds that dry mouth often follows stomach symptoms, including nausea, eating and drinking less, and slower stomach emptying. Another 2026 review says reduced fluid intake and possible salivary changes lie behind the complaints people call Ozempic mouth.
The first review is plain about its limits: the evidence remains limited and largely indirect.
Sources: GLP-1 oral and salivary effects review, 2026; Semaglutide oral effects review; Incretin oral health review, 2026
What studies of GLP-1 drugs found about dry mouth
The studies point in different directions, and none tested tirzepatide alone. Small reports find dry mouth; a large record study found lower odds for several salivary conditions.
| Study | Type | Finding | Limit |
|---|---|---|---|
| Case series, 2023 | Three patients on semaglutide | Secondary dry mouth; saliva flow back to acceptable after care | Three people, one drug, no comparison group |
| Otolaryngologic analysis, 2025 | Safety signal analysis | Significant signal for dry mouth with semaglutide | Signals show association, not cause |
| Orofacial matched cohort, 2026 | Health records, GLP-1 users vs matched controls | No higher risk for most outcomes; inverse associations for several salivary conditions | Drug class, not tirzepatide alone |
| Oral and salivary review, 2026 | Review of case and safety reports | Dry mouth, low saliva, taste change, mouth and throat discomfort reported | Evidence limited and largely indirect |
The matched cohort found that GLP-1 therapy did not increase risk for most mouth and face outcomes, and showed significant inverse associations for several mucosal, nerve, salivary and dental conditions. That cuts against the small reports, and it does not settle the question either way.
A 2026 dental review lists what dentists may see in people taking semaglutide: dry mouth, bad breath, enamel erosion tied to vomiting, and altered taste. Another 2026 review notes that human data on oral health outcomes remain scarce, with much of the evidence coming from lab work, indirect data, or case and safety reports.
Sources: Semaglutide case series, 2023; Otolaryngologic side effects analysis, 2025; Orofacial matched cohort, 2026; GLP-1 oral and salivary effects review, 2026; Semaglutide dental guidelines review, 2026; Incretin oral health review, 2026
Taste changes on the Zepbound label
Taste change sits near dry mouth in the label. The Zepbound label reports dysgeusia (a change in taste) in 0.4% of Zepbound users and in no one on placebo. The 2026 oral and salivary review also lists taste change among the mouth effects reported with GLP-1 drugs.
Sources: Zepbound FDA label; GLP-1 oral and salivary effects review, 2026
Dry mouth relief on GLP-1 drugs: what is on record
No trial has tested a treatment for dry mouth on Zepbound or semaglutide. The only record of what clinicians did is a 2023 case series of 3 semaglutide users.
In that series, management varied between stopping the drug, the use of pilocarpine (a prescription medicine that raises saliva flow), and simple symptom care. The paper reports that the patients resumed acceptable saliva flow.
Three cases cannot show which step worked or whether it would work for anyone else. The one label instruction that applies is about fluids: the Zepbound patient information says it is important to drink fluids to help reduce the chance of dehydration.
Choices about stopping a medicine or adding one belong with a licensed clinician, and a dentist can check the mouth itself. For the other side effects of this drug group, see our GLP-1 side effects guide.
Zepbound dry mouth questions
Is dry mouth a side effect of Zepbound?+
Yes, at a low rate. The Zepbound label says dry mouth or dry throat was reported by 1% of people on Zepbound and 0.1% on placebo in Studies 1 and 2 pooled. That is below the 2% cut-off for the main side effect table, so it is listed in a separate paragraph.
Can Zepbound dehydrate you?+
The label says it can lead to fluid loss through side effects. The patient information says diarrhea, nausea and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems, and that it is important to drink fluids to help reduce the chance of dehydration.
Why does Zepbound make me so thirsty?+
Thirst is not on the Zepbound label: a full-text search found no entry for it. What the label does report is dry mouth or dry throat (1% vs 0.1%) and fluid loss from diarrhea, nausea and vomiting. Thirst that is new or strong is a question for a clinician.
How to get rid of dry mouth from semaglutide?+
No trial has tested a fix. A 2023 case series of 3 semaglutide users says management varied between stopping the drug, the saliva medicine pilocarpine, and symptom care, and the patients resumed acceptable saliva flow. Three cases cannot show what works in general, so this is a question for a clinician or dentist.
Does the Mounjaro label list dry mouth?+
No. A full-text search of the US Mounjaro label found no entry for dry mouth, dry throat or xerostomia. The Zepbound label, for the same drug, does list dry mouth or dry throat at 1% against 0.1% on placebo.
What is Ozempic mouth?+
It is an informal name, not a diagnosis. A 2026 review says reduced fluid intake and possible salivary changes underlie a cluster of patient-reported complaints colloquially termed Ozempic mouth. The same review says human data on oral health outcomes remain scarce.
Sources: Zepbound FDA label; Mounjaro FDA label; Semaglutide case series, 2023; Incretin oral health review, 2026
Related tirzepatide guides
This guide is for educational purposes only and is not medical advice. It describes what FDA labels and published studies report about dry mouth on tirzepatide and other GLP-1 drugs. Questions about your own symptoms or medicine belong with a licensed clinician.